FDA approved

FDA Approves 3D printed tablets (Aprecia Pharmaceuticals, Blue Ash, OH)

 zipdoseFDA has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy.

SPRITAM utilizes Aprecia’s proprietary ZipDose® Technology platform, that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.1 While 3DP has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA.

ZipDose® Technology product candidates are intended to improve the patient experience and help increase adherence by being designed to1:

  • Rapidly disintegrate in less than 10 seconds—a previously unachievable rate for high-dose formulations (based on demonstrator development testing)
  • Offer a wider range of taste-masking capabilities than were previously possible

FDA Approves DELTOID Injection Site for Abilify Maintena® (aripiprazole) for extended-release injectable suspension in the Treatment of Schizophrenia (Otsuka Pharmaceuticals, Princeton, NJ)

MaintenaPatients being treated for schizophrenia now have a new administration site option 

Approval based on data demonstrating  comparable pharmacokinetics, tolerability and safety of deltoid vs gluteal administration

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s